Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction
开发一种有效策略来阻断 AAV 脑转导的 Nab 活性
基本信息
- 批准号:10600969
- 负责人:
- 金额:$ 26.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAffectAffinityAnimalsAntibodiesAntibody titer measurementAntigen-Antibody ComplexAntigensB-LymphocytesBindingBinding ProteinsBiologicalBlindnessBlood Coagulation DisordersBlood Component RemovalBrainBrain DiseasesCapsidCellular TropismCentral Nervous SystemCentral Nervous System DiseasesChemicalsChromosomesClinicalClinical ResearchClinical TrialsControl GroupsDNA Sequence AlterationDataDependenceDependovirusDevelopmentDiseaseDoseEngineeringFDA approvedFamily suidaeGene DeliveryGenetic DiseasesHigh PrevalenceHumanImmunizationImmunizeImmunoglobulinsImmunologicsIn VitroIndividualInjectionsIntravenous ImmunoglobulinsIntraventricularIntraventricular InjectionsLightMarketingMediatingMedicineMendelian disorderModificationMusMuscular AtrophyMycoplasmaNatureOrphan DrugsPatientsPeptide HydrolasesPharmaceutical PreparationsPhasePlasmaPopulationPreparationProductionProteinsQuality of lifeRare DiseasesRouteSafetySerotypingSerumSpinalStructureTechnologyTherapeuticVertebral columnWorkadeno-associated viral vectorclinical developmentcomparison controlefficacy testinggene therapyimproved outcomein vitro activityintravenous injectionmortalitymultiple myeloma M Proteinmutantnervous system disorderneutralizing antibodynovelpreventprotective effectrare genetic disorderside effectsuccesstargeted treatmenttechnology developmenttooltransduction efficiencytransgene expressionvectorvirus tropism
项目摘要
Adeno-associated virus (AAV) vectors have been successfully employed in patients with rare neurological
diseases. Recently, two AAV based gene therapy drugs have been approved by the FDA, Luxturna been
valued at $850,000 with a one-time application for blindness and Zolgensma at $2,100,000 for spinal muscle
atrophy. AAV vector mediated gene therapy has shown to be a potentially huge market. Although successful in
clinical studies for neurological disorders, one of the major concerns for effective AAV brain application is high
prevalence of neutralizing antibody (Nab) in humans. In the general human population, over 95 % of
individuals are infected by AAV and, on average, 50 % of them develop Nabs. The inhibition effect of Nabs on
AAV brain transduction has been well documented regardless of delivery routes (direct intra-brain injection or
systemic administration). Several approaches have been exploited to escape AAV Nabs, including chemical
modification, use of different AAV vector serotypes, AAV capsid engineering, and biological depletion of Nab
titer (empty capsid utilization, B cell depletion, plasma-apheresis, and Ig proteases). Generally, these
approaches have low efficiency, unwanted side effects, or AAV tropism change. Recently, Nabgen has
developed a vector independent protein-based strategy to universally block Nabs using a unique mycoplasma
derived protein, termed Protein-M. Protein-M is able to interact with immunoglobulin from any species without
antigen dependence by binding to variable regions on the antibody light and heavy chains. Using human IVIG
and serum from AAV immunized mice, we have found that Protein-M reduced AAV vector neutralization over
100 fold when compared to control group without Protein-M in vitro. Most importantly, we have observed that
Protein-M was able to retain AAV transduction over 1000 fold in mice with adoptive transfer of Nab positive
serum. So far, this is the most effective strategy to evade AAV Nabs. To explore the application of Protein-M in
patients with AAV brain targeted therapy, it is imperative to address the efficacy of Protein-M to protect AAV
from Nabs for brain transduction in subjects with Nabs. In this proposal, we will first study the effect of Protein-
M co-administered with AAV vectors on AAV Nab blockage via direct injection into the brain in mice with pre-
immunization of AAV (Aim 1). Next, we will study the effect of Protein-M via systemic injection on brain
transduction after direct delivery of AAV vectors (Aim 2). If successful, this novel and effective technology will
extend the benefits of AAV targeted gene therapy to every patient with brain disorders and AAV Nabs.
腺相关病毒(AAV)载体已成功地应用于罕见的神经系统疾病患者
疾病。最近,两种基于AAV的基因治疗药物已经获得FDA的批准,Luxturna被批准
价值850,000美元,一次性申请失明,Zolgensma,脊柱肌肉,2,100,000美元
萎缩。AAV载体介导的基因治疗已被证明是一个潜在的巨大市场。虽然在
神经疾病的临床研究,有效应用AAV脑的主要关注点之一是高
中和抗体(NAB)在人类中的流行率。在普通人口中,超过95%的人
个人感染甲型流感病毒,平均有50%的人患上新城疫。NaBS对小鼠肺泡巨噬细胞的抑制作用
AAV脑转导已经被很好地记录下来,而不考虑传递途径(直接脑内注射或
系统管理)。已经利用了几种方法来逃避AAV Nabs,包括化学
不同AAV载体血清型的修饰、使用、AAV衣壳工程和NAB的生物耗竭
效价(空衣壳利用率、B细胞耗竭、血浆分离和Ig蛋白水解酶)。一般而言,这些
治疗方法效率低、副作用大或AAV取向改变。最近,纳布根已经
开发了一种基于载体的非依赖蛋白质的策略,利用一种独特的支原体普遍阻断NAB
衍生蛋白质,称为蛋白质-M。蛋白-M能够与任何物种的免疫球蛋白相互作用,而不需要
通过结合抗体轻链和重链上的可变区来依赖抗原。使用人类静脉注射免疫球蛋白
和AAV免疫小鼠的血清,我们发现Protein-M降低了AAV载体的中和能力。
与不加蛋白-M的对照组相比,在体外是对照组的100倍。最重要的是,我们观察到
在过继转移NAB阳性的小鼠中,Protein-M能够保留1000倍以上的AAV转导
血清。到目前为止,这是规避AAV NAB最有效的策略。探讨蛋白质-M在生物医学中的应用
AAV患者脑内靶向治疗,解决蛋白-M对AAV的保护作用势在必行
用于NABS受试者的脑传导。在这项提案中,我们将首先研究蛋白质的影响-
小鼠脑内直接注射M与AAV载体联合应用阻断AAV NAB的实验研究
甲型肝炎病毒免疫(目标1)。接下来,我们将研究蛋白-M通过全身注射对大脑的影响
AAV载体直接传递后的转导(目标2)。如果成功,这项新颖而有效的技术将
将AAV靶向基因治疗的好处扩大到每一位患有脑部疾病和AAV NAB的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles H Askew其他文献
Charles H Askew的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 26.96万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 26.96万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 26.96万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 26.96万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 26.96万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 26.96万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 26.96万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 26.96万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 26.96万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 26.96万 - 项目类别: